Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed exchange traded fund launched on October 21, 2013.

Zacks Investment Research • Jul 14, 2026

FHLC vs. BBH: Which Healthcare ETF Is the Better Buy?

Fidelity MSCI Health Care Index ETF (FHLC) provides broad sector exposure with significantly lower fees than VanEck Biotech ETF (BBH). BBH focuses on just 25 holdings in the biotech space while FHLC holds more than 300 positions across the entire healthcare industry.

The Motley Fool • Jul 4, 2026

Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It

Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.

Seeking Alpha • Jun 29, 2026

Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value?

iShares Global Healthcare ETF provides exposure to international markets, while Fidelity MSCI Health Care Index ETF focuses exclusively on U.S.-based companies. Fidelity MSCI Health Care Index ETF maintains a significantly lower expense ratio than iShares Global Healthcare ETF.

The Motley Fool • Jun 26, 2026

FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026?

Fidelity MSCI Health Care Index ETF (FHLC) offers a lower expense ratio and higher dividend than the iShares U.S. Healthcare ETF (IYH). IYH maintains a more concentrated portfolio, with 101 holdings compared to FHLC's 338 positions.

The Motley Fool • Jun 16, 2026

If You Hold This Healthcare ETF, You're Losing Big

The Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) is down about 5% year to date while the S&P 500 is up 7%.

24/7 Wall Street • May 19, 2026

Medical Technology Stocks: Innovation Endures As Valuations Reset

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Seeking Alpha • May 2, 2026

Trump's Psychedelics Stance Reignites Sector - How Investors Can Benefit

Recent White House and FDA actions fast-track psychedelic depression drug approvals, granting priority review vouchers and accelerating rescheduling for eligible therapies. Compass Pathways leads with a CNPV for COMP360 in treatment-resistant depression, positive Phase 3 data, and a sub-$1bn market cap suggesting potential upside.

Seeking Alpha • Apr 27, 2026

What Johnson & Johnson Earnings Signal for Healthcare ETFs

With Q1 earnings season well underway, it was Johnson & Johnson (JNJ) giving investors a peek at how the broader healthcare sector might perform. The healthcare giant beat expectations on Tuesday in revenue ($24.1 billion actual versus $23.6 expected) and earnings per share ($2.70 actual versus $2.66 expected).

ETF Trends • Apr 14, 2026

Global PMI: Tracking The Sectors Hit Hardest By The Middle East War

Survey data underscored how the war in the Middle East has already had a material impact on economic growth around the world. Drilling down deeper, the data showed weaker growth trends were recorded across all major industries globally.

Seeking Alpha • Apr 12, 2026